Advertisement EastGate augments sub-micron self-nanoemulsifying platform technology - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

EastGate augments sub-micron self-nanoemulsifying platform technology

US-based pharmaceutical firm EastGate Acquisitions is augmenting its self-emulsifying sub-micron platform technology to include a broad spectrum of delivery options, which are directed towards improving patient compliance.

These technologies are applicable to EastGate’s existing pharmaceutical products in development and can also be employed as effective platforms for delivery of other biologically active compounds.

The company recently expanded its new product development to include large molecules as active compounds to address indications in diabetes, obesity and the overall metabolic syndrome.

The technology platform led to the development of several improved new formulations and alternative dosage forms for delivery of known biologically active molecules.

The company said that the technology uses its sub-micron self-emulsifying delivery vehicle and facilitates the creation of harmonized formulations with better drug absorption.

At present, the company is working towards acquiring the licensing rights to develop and manufacture an intraoral insulin formulation.

According to the company, the intraoral insulin dosage forms under consideration are liquid and solid dosage forms, such as compressed tablet which can be delivered to the mouth for intraoral absorption.

EastGate CEO Anna Gluskin said the company has recognized the importance of expanding its sub-micron self-nanoemulsifying platform technology to include different dosage forms and delivery methods.

"The versatility of the sub-micron platform technology will continue to validate the company’s sub-micron approach and provide a unique opportunity to offer different absorption-enhanced products to widen the target patient population," Gluskin said.